Trials / Completed
CompletedNCT00565279
Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis
Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Astion Pharma A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASF1057 | Twice daily, topical |
| DRUG | ASF1057 | Twice daily, Topical |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-05-01
- Completion
- 2008-06-01
- First posted
- 2007-11-29
- Last updated
- 2008-06-03
Source: ClinicalTrials.gov record NCT00565279. Inclusion in this directory is not an endorsement.